← ANALYST RATINGS · TIPRANKS
Immunovant (IMVT): analyst forecast and price target
Analyst consensus
Moderate Buy7 Buy3 Hold0 Sell
Ratings of 10 analysts in the last 3 months12-month forecast
Based on 10 price targets given in the last 3 months, the average target is $49.22, the highest $66.00, the lowest $37.00. The average is +84.1% from the last price of $26.73.
Analyst ratings 16
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $29.00 → $28.00−3.4% | Hold | +4.8% | Reiterated | 17.10.26on TipRanks Oct 16 22:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $29.00 → $28.00−3.4% | Hold | +4.8% | Reiterated | 17.10.26on TipRanks Oct 16 22:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $29.00 → $28.00−3.4% | Hold | +4.8% | Reiterated | 15.10.26on TipRanks 14:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $29.00 → $28.00−3.4% | Hold | +4.8% | Reiterated | 15.10.26on TipRanks 14:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $28.00 → $27.00−3.6% | Hold | +1.0% | Reiterated | 15.10.26on TipRanks 14:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $30.00 → $29.00−3.3% | Hold | +8.5% | Reiterated | 15.10.26on TipRanks 14:05 | — | |
| Dina Ramadane★★★★★★★★★★#5584 · hits 75% · avg +7.8% | Bank of America Securities | $45.00 | Buy | +68.4% | Reiterated | 12.10.26on TipRanks 08:20 | −3.2%next day −2.6% | ↗ |
| Sam Slutsky★★★★★★★★★★#35 · hits 55% · avg +49.4% | LifeSci Capital | $53.00 | Buy | +98.3% | Reiterated | 26.09.26on TipRanks 10:30 | +1.3%next day +0.1% · 5 days −1.9% | ↗ |
| Eve Burstein★★★★★★★★★★#1300 · hits 72% · avg +25.0% | Bernstein | $37.00 | Hold | +38.4% | Reiterated | 25.09.26on TipRanks Sep 26 09:00 | −2.6%next day +1.3% · 5 days +1.2% | ↗ |
| Danielle Brill★★★★★★★★★★#566 · hits 56% · avg +16.1% | Truist Financial | — | Hold | — | Reiterated | 24.09.26on TipRanks 07:15 | −1.5%next day −2.6% · 5 days −0.6% | ↗ |
| Douglas Tsao★★★★★★★★★★#207 · hits 56% · avg +24.3% | H.C. Wainwright | $41.00 | Buy | +53.4% | Reiterated | 23.09.26on TipRanks 13:16 | −6.7%next day −1.5% · 5 days −1.5% | ↗ |
| Yasmeen Rahimi★★★★★★★★★★#160 · hits 51% · avg +36.0% | Piper Sandler | $66.00 | Buy | +146.9% | Reiterated | 21.09.26on TipRanks 06:55 | −0.9%next day +0.3% · 5 days −8.9% | ↗ |
| Unknown Analyst | UBS | $24.00 → $40.00+66.7% | Hold | +49.6% | Assigned | 24.08.26on TipRanks Aug 27 04:05 | −2.1%next day +0.1% · 5 days −6.2% | ↗ |
| Alex Thompson CFA★★★★★★★★★★#60 · hits 73% · avg +50.6% | Stifel Nicolaus | $49.00 → $57.00+16.3% | Buy | +113.2% | Reiterated | 11.08.26on TipRanks Aug 12 22:05 | +2.9%next day +3.8% · 5 days +8.6% | ↗ |
| Brian Cheng★★★★★★★★★★#1122 · hits 55% · avg +14.0% | J.P. Morgan | $50.00 | Buy | +87.1% | Reiterated | 10.08.26on TipRanks 07:40 | −0.1%next day +2.9% · 5 days +9.6% | ↗ |
| Leland Gershell★★★★★★★★★★#2332 · hits 40% · avg +6.2% | Oppenheimer | $54.00 | Buy | +102.0% | Reiterated | 07.08.26on TipRanks 08:45 | −0.1%next day −0.1% · 5 days +4.3% | ↗ |
| Samantha Semenkow★★★★★★★★★★#6889 · hits 47% · avg +0.7% | Citi | $57.00 → $61.00+7.0% | Buy | +128.2% | Reiterated | 30.06.26on TipRanks 06:45 | −0.7%next day −0.9% · 5 days +4.8% | ↗ |
| Yatin Suneja★★★★★★★★★★#120 · hits 57% · avg +33.0% | Guggenheim | $44.00 → $62.00+40.9% | Buy | +131.9% | Reiterated | 26.05.26on TipRanks 06:50 | −1.6%next day −1.2% · 5 days −9.8% | ↗ |
| Derek Archila★★★★★★★★★★#252 · hits 58% · avg +22.7% | Wells Fargo | $45.00 | Buy | +68.4% | Reiterated | 21.05.26on TipRanks 05:10 | −4.2%next day −0.3% · 5 days −4.3% | ↗ |
| Corinne Johnson★★★★★★★★★★#1634 · hits 55% · avg +11.6% | Goldman Sachs | $29.00 → $32.00+10.3% | Hold | +19.7% | Assigned | 15.04.26on TipRanks 07:15 | +2.5%next day −0.5% · 5 days +5.9% | ↗ |
| Andy Chen★★★★★★★★★★#959 · hits 67% · avg +28.8% | Wolfe Research | $47.00 | Buy | +75.8% | Reiterated | 06.04.26on TipRanks Apr 7 08:15 | +1.1%next day −1.2% · 5 days −3.2% | ↗ |
| Thomas Smith★★★★★★★★★★#45 · hits 57% · avg +51.1% | Leerink Partners | $52.00 → $50.00−3.8% | Buy | +87.1% | Reiterated | 02.04.26on TipRanks 11:35 | −2.5%next day +1.1% · 5 days −3.6% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Immunovant
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $49.22 at a price of $33.78 (+45.7%); now: $49.22 at $26.73 (+84.1%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 10 | 11 | 3 | 2 | 4 | 5 |
| Buy | 7 | 7 | 8 | 8 | 9 | 8 |
| Hold | 3 | 2 | 1 | 2 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 30.10.26 (Q2 2027, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.74 (from $-0.79 to $-0.63). Last quarter: $-0.75.
Best top-analyst consensus in the sector · Healthcare
About Immunovant
- CEO: Eric Venker
- Employees: 315
- 1000 Park Forty Plaza, Durham, NY, 27713, US
- immunovant.com
Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases. Batoclimab is currently undergoing Phase IIa clinical evaluations for treating both myasthenia gravis and thyroid eye disease. Additionally, it has commenced Phase II clinical studies for patients suffering from warm autoimmune hemolytic anemia. Established in 2018, Immunovant operates from its headquarters in New York, New York, functioning as a subsidiary under the umbrella of Roivant Sciences Ltd.
Data from the stock’s TipRanks forecast page, read 9 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗